본문 바로가기

Main Tasks

A vision-driven and value-generating global healthcare group

  • Home
  • R&D
  • Main Tasks

Main Tasks

  • Lasmiditan

    Innovative Migraine Treatment

    • Original Developer : CoLucid Pharmaceuticals (acquired by Lilly in Jan 2017)
    • Mechanism of Action : A 5-HT1F (serotonin) ditan drug for the treatment of acute migraines.
    • Features : Whereas conventional triptan drugs are associated with cardiovascular contraction due to the actions of 5-HT1B,D as one of their side effects, Lasmiditan differs in that it acts quickly with minimal side effects. (an alternative treatment for migraine sufferers diagnosed with or at the risk of developing a cardiovascular disease)
    • Schedule : License application in 2018 (tentative)
    • Licensing : Completed in 2013, distribution rights in South Korea and eight ASEAN countries.
  • Targeted Agent (IDX-1197)

    Personalized Tumor Treatment through Inhibition of the PARP-1 Protein

    • A targeted anticancer drug that prevents the survival and maintenance of cancer by inhibiting the damage-recovery system of cancer cells (PARP1).
    • Proven superior anticancer properties against HRD-related ovarian cancer, pancreatic cancer, breast cancer, and prostate cancer.
    • Patents: Patents filed in 14 countries (US, Europe, Russia, China, and Japan). Patent registration completed in Australia.
    • Best in Class (cf. AstraZeneca “Lynparza” (Ingredient: Olaparib))
  • Targeted Agent (IDX-11774)

    Global Out-Licensing of HIF Control Agent

    • Suppresses hypoxia-inducible factors, which promote the formation and metastasis of cancer.
    • Powerful synergistic effects when administered concurrently with a immunotherapy cancer drug.
    • Effectively suppresses the growth and metastasis of tumors in the large intestines, kidneys, lungs, and other organs.
    • First in Class (first HIF-targeting agent, oral administration)
  • Biobetter (IDB-0062)

    Next-Gen Eye Disease Treatment

    • A safe, Lucentis-based biobetter.
    • Possibility of increased efficacy, resistance elimination, and improved patient convenience through fusion of functional peptides.
    • Possible to administer on patients who are resistant to or do not respond to Lucentis and possible to expand indication to include diabetic retinopathy.
    • Possibility of future development as eye drops through formulation improvements confirmed.
  • Biobetter (IDB-0072)

    New Dual-Target Antibody Cancer Drug

    • Avastin-based biobetter.
    • Able to treat non-responsive and resistant patients through suppression of various vascular endothelial growth factors and vessel stabilization.
    • Reduced dose for lower possibility of side effects and increased cost-effectiveness.
    • Potential applications with anticancer drugs whose indications have been revoked due to lack of efficacy.
  • New Botanical Drug (ID-1201)

    New Botanical Drug for Treatment of Alzheimer’s

    • Chinaberry extracts proven for the first time to be effective at countering the effects of Alzheimer’s disease.
    • Powerful suppression of Alzheimer’s (animal model).
    • Overcomes the limitations of single-target treatments (multiple control).
    • Alleviation of symptoms and treatment of disease.
    • Currently in a phase II clinical study (South Korea).
  • Hepatitis B Treatment (Besifovir)

    • Currently in a phase III clinical study in 28 hospitals throughout South Korea (proven to be highly effective at treatment hepatitis B and at virus removal).
    • Phase I and phase II clinical studies have shown low levels of nephrotoxicity and bone loss, which are two major side effects of conventional hepatitis treatments.
    • Since there is also no indication of drug resistance, a key reason for avoiding conventional hepatitis treatments, expectations for this new drug are high.
    • With cases of resistance to conventional drugs becoming increasingly more frequent, there is now great demand for a new type of hepatitis treatment.
TOP